ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag funding genetics genomics cancer neuroscience

2022 Top 10 Innovations 
2022 Top 10 Innovations
The Scientist | Dec 12, 2022 | 10+ min read
This year’s crop of winning products features many with a clinical focus and others that represent significant advances in sequencing, single-cell analysis, and more.
A Nile rat sitting atop fruits
Genome Spotlight: Nile Rat (Avicanthis niloticus)
Christie Wilcox, PhD | Nov 23, 2022 | 4 min read
A reference sequence for this emerging model organism will facilitate research on type 2 diabetes and the health effects of circadian rhythm disruption.
The Psychiatrist’s Jigsaw
Megan Scudellari | Nov 1, 2013 | 10+ min read
Researchers are piecing together the devilishly complex sets of genetic alterations underlying schizophrenia and bipolar disorder.
Collage of faces
Remembering Those We Lost in 2022
Lisa Winter | Dec 26, 2022 | 5 min read
A look at some noteworthy scientists who died this year, leaving behind a legacy of research excellence.
The Human Genome
Arielle Emmett | Jul 23, 2000 | 10+ min read
Life sciences took center stage virtually around the world June 26. President Bill Clinton, flanked on the left by Celera Genomics Group president J. Craig Venter and on the right by National Human Genome Research Institute director Francis S. Collins, announced the completion of "the first survey of the entire human genome."
Can Viruses in the Genome Cause Disease?
Katarina Zimmer | Jan 1, 2019 | 10+ min read
Clinical trials that target human endogenous retroviruses to treat multiple sclerosis, ALS, and other ailments are underway, but many questions remain about how these sequences may disrupt our biology.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
Watson Departure Vexes Genome Experts
Scott Veggeberg | May 24, 1992 | 4 min read
They fear that funding support for their vast gene-mapping project could erode now that the Nobelist is leaving While the head of the nation's premier health agency may not be losing sleep over the resignation of James Watson as head of the Human Genome Project (HGP), many genetic researchers are distressed to see him go. Genome scientists interviewed for this article say it will be difficult for the National Institutes of Health, via its search committee, to find someone with the same drive
Opinion: The Payoff of Big Science
K. John Morrow Jr. | Jun 3, 2013 | 4 min read
Was the Human Genome Project the key to a gold mine?
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard

Run a Search

ADVERTISEMENT